one-sided / two-sided [General Sta­tis­tics]

posted by ElMaestro  – Denmark, 2019-03-04 10:04 (1841 d 22:36 ago) – Posting: # 19997
Views: 4,166

Hi Hötzi,


❝ In other words, if patients are treated with the originator’s product, there is a 5% risk that it does not perform better (more efficient and/or safer) than placebo.


There is no more than a 5% risk of approving the test product (=concluding superiority) if the test product is not superior.

❝ If we would test for BE at the 2.5% level (95% CI) we would be overly strict and at the same time gain absolutely nothing in terms of the patient’s risk.


The patient's risk would be halved (max 2.5% chance of approving a non-BE product; CIs would get wider).

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
22,940 posts in 4,812 threads, 1,640 registered users;
49 visitors (0 registered, 49 guests [including 5 identified bots]).
Forum time: 08:40 CET (Europe/Vienna)

Those people who think they know everything
are a great annoyance to those of us who do.    Isaac Asimov

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5